Enfortumab Vedotin Used for Neoadjuvant and Adjuvant Bladder Cancer, PW Reports
Enfortumab vedotin, an antibody-drug conjugate previously approved for locally advanced or metastatic urothelial carcinoma and as a first-line combination treatment, can now be applied as a neoadjuvant treatment and following radical cystectomy, Pharmaceutisch Weekblad reported.
Key Clinical Takeaways:
- Enfortumab vedotin expands its clinical utility to include neoadjuvant and adjuvant settings.
- The therapy functions as an antibody-drug conjugate that targets nectin-4 on cancer cell surfaces.
- Internalization and subsequent enzymatic cleavage release monomethyl auristatine E to inhibit cell division and induce apoptosis.
Mechanism of Action and Cellular Target
First commercialized in 2019, enfortumab vedotin is classified as an antibody-drug conjugate. The agent binds specifically to nectin-4, an adhesion protein expressed on the surface of urothelial carcinoma cells. Following this binding event, the drug-conjugate complex is internalized into the cell where it undergoes cleavage by lysosomal proteases.
This intracellular cleavage releases monomethyl auristatine E, commonly known as MMAE. As an antimitotic agent, MMAE binds directly to microtubules within the cell. This action halts cellular division and ultimately induces apoptosis, providing the biological basis for its cytotoxicity against tumor cells.
Expanded Therapeutic Indications in Bladder Cancer
The latest regulatory and clinical updates broaden the utility of enfortumab vedotin across different stages of bladder cancer management. Previously, the agent was deployed as a monotherapy for locally advanced or metastatic urothelial carcinoma, as well as in combination with pembrolizumab for first-line treatment of unresectable or metastatic disease.
The updated clinical approach integrates the treatment into earlier disease stages. Clinicians can now administer enfortumab vedotin in combination with pembrolizumab prior to surgery as a neoadjuvant therapy. The protocol also permits its use as an adjuvant treatment following radical cystectomy.
Clinical data supporting these expanded indications reflect ongoing developments in perioperative systemic therapy regimens for bladder cancer management. Treatment decisions in these settings typically require coordination with specialized urologic oncologists and medical oncology teams.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.